Carter Alan W
MRIGlobal, University of Missouri-Kansas City, Kansas City, MO
J Diabetes Sci Technol. 2016 Aug 22;10(5):1188-91. doi: 10.1177/1932296816629488. Print 2016 Sep.
The future biosimilar insulin marketplace could be a bane, benefit, or something in between, to patients under our care in the United States. Formulary preferred product status, with or without FDA interchangeability designation, coupled with current and proposed state pharmacy substitution laws may lead to an environment with as many as 50 different substitution guidelines depending on in which state a patient presents his or her prescription to be filled. If online global prescription supply options, often referred to as "Canada Drug," are utilized, other country substitution guidelines come into play, which may yield a recipe for confusion, if not disaster.
未来生物类似物胰岛素市场对于我们在美国所护理的患者而言，可能是祸、是福，或者介于两者之间。无论有无美国食品药品监督管理局（FDA）的可互换性认定，处方集首选产品地位，再加上现行和拟议的州药房替代法律，可能会导致一种情况：根据患者提交其待配药处方的州不同，会有多达50种不同的替代指南。如果使用通常被称为“加拿大药品”的在线全球处方供应选项，其他国家的替代指南就会起作用，这可能会造成混乱局面，甚至是灾难。
